TNF GENE REGULATION IN BREAST AND OVARY CANCER
TNF GENE REGULATION IN BREAST AND OVARY CANCER
批准号:
2105936
负责人:
DAVID R SPRIGGS
金额:
$16.15万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-05-01 至 1998-02-28
关键词:
autocrine breast neoplasms carcinoma epithelium female gel mobility shift assay gene deletion mutation genetic regulation human subject molecular oncology nucleic acid structure ovary neoplasms protooncogene reporter genes squamous cell carcinoma tissue resource /registry transcription factor tumor necrosis factor alpha women's health
中文摘要
点击翻译按钮获取中文摘要
英文摘要
There is growing evidence that TNF-alpha may play an important role in
the pathogenesis of some malignancies. It appears that production of
TNF-alpha by malignant cells occurs in some human cancers including
ovarian cancer and neuroblastoma. In human ovarian cancer, TNF-alpha has
been implicated as a paracrine and autocrine growth factor. TNF-alpha
may also increase chemosensitivity to certain drugs including taxol and
cisplatin, the most active drugs in the treatment of ovary cancer.
Autocrine production of TNF-alpha produces resistance to the
antiproliferative effects of TNF-alpha in epithelial cancer cells.
However, the regulation of TNF-alpha expression in malignant epithelial
cells is very poorly understood. This renewal represent extension of
previous studies of TNF-alpha gene regulation in human epithelial cancer
cells. Breast and ovary cancer models of autocrine TNF-alpha production
first identified in our laboratory will be utilized. We will examine the
molecular biology of TNF-alpha gene regulation in human epithelial cancer
cells through studies of both the 5' flanking region and the 3' region
of the human TNF-alpha gene. Early response genes, including c-fos and
the jun family appear to be key participants in epithelial tumor cell
regulation of TNF-alpha. These laboratory studies will be accompanied
by studies of clinical samples from patients with ovarian carcinoma to
examine the importance of TNF-alpha in ovarian cancer pathogenesis.
The specific aims will be: 1. To investigate the importance of the TNF-
alpha 5' flanking region in the regulation of TNF-alpha gene regulation
in human breast and ovary cancer cells through reporter gene constructs
and gel shift assays; 2. To investigate the importance of the AP-1 motif
in the control of TNF production in human epithelial cancer cells with
sense and antisense c-jun constructs; 3. To evaluate the role of the
TNF-alpha 3' flanking region in the regulation of TNF-alpha protein
production in human epithelial cancer cells with 3' flanking region
reporter gene constructs; 4. To examine human epithelial ovarian cancers
from our ovarian cancer tissue bank to better define the relationships
between TNF-alpha expression and ovarian cancer pathophysiology. Taken
together, these studies will provide insight into the pathobiology of
ovarian cancer and possibly provide new strategies for ovarian cancer
therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Career Enhancement Program (CEP)
-
批准号:10228056
-
项目类别:
-
资助金额:$13.31万
-
财政年份:2020
-
负责人:DAVID R SPRIGGS
-
依托单位:
Career Enhancement Program (CEP)
-
批准号:10024422
-
项目类别:
-
资助金额:$9.94万
-
财政年份:2020
-
负责人:DAVID R SPRIGGS
-
依托单位:
MUC16 Antibody Based Strategies for Imaging and Therapy
-
批准号:8933340
-
项目类别:
-
资助金额:$58.01万
-
财政年份:2015
-
负责人:DAVID R SPRIGGS
-
依托单位:
Immunologic Approaches to Ovarian Cancer
-
批准号:8933336
-
项目类别:
-
资助金额:$205.28万
-
财政年份:2015
-
负责人:DAVID R SPRIGGS
-
依托单位:
Career Development Program
-
批准号:7976145
-
项目类别:
-
资助金额:$4.55万
-
财政年份:2010
-
负责人:DAVID R SPRIGGS
-
依托单位:
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
-
批准号:7886165
-
项目类别:
-
资助金额:$71.78万
-
财政年份:2009
-
负责人:DAVID R SPRIGGS
-
依托单位:
Novel Strategy for Clinical Remission in Ovarian Cancer
-
批准号:6952125
-
项目类别:
-
资助金额:$10.28万
-
财政年份:2005
-
负责人:DAVID R SPRIGGS
-
依托单位:
CORE--PHARMACOLOGY
-
批准号:6664391
-
项目类别:
-
资助金额:$18.86万
-
财政年份:2002
-
负责人:DAVID R SPRIGGS
-
依托单位:
CORE--BIOSTATISTICS
-
批准号:6664390
-
项目类别:
-
资助金额:$18.86万
-
财政年份:2002
-
负责人:DAVID R SPRIGGS
-
依托单位:
DEVELOPMENTAL CHEMOTHERAPY
-
批准号:6664387
-
项目类别:
-
资助金额:$18.86万
-
财政年份:2002
-
负责人:DAVID R SPRIGGS
-
依托单位:
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT
-
批准号:6191348
-
项目类别:
-
资助金额:$10.56万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER
-
批准号:6489335
-
项目类别:
-
资助金额:$23.89万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT
-
批准号:6522824
-
项目类别:
-
资助金额:$10.35万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
Clinical Investigator Development in Solid Tumor Oncology
-
批准号:7661663
-
项目类别:
-
资助金额:$15.31万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER
-
批准号:6032451
-
项目类别:
-
资助金额:$22.94万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER
-
批准号:6712834
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
Clinical Investigator Development in Solid Tumor Oncology
-
批准号:7492614
-
项目类别:
-
资助金额:$15.31万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NF-KB MEDIATED DRUG RESISTANCE IN OVARIAN CANCER
-
批准号:6626725
-
项目类别:
-
资助金额:$24.39万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
NEW INVESTIGATOR TRAINING IN DRUG DEVELOPMENT
-
批准号:6801829
-
项目类别:
-
资助金额:$10.4万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
Clinical Investigator Development in Solid Tumor Oncology
-
批准号:7880842
-
项目类别:
-
资助金额:$15.31万
-
财政年份:2000
-
负责人:DAVID R SPRIGGS
-
依托单位:
海外基金